Intensity Therapeutics   Report issue

For profit Phase 2
Founded: Norwalk CT United States (2012)

Organization Overview

First Clinical Trial
2017
NCT03058289
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Intensity Therapeutics, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

int230-6 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Bile Duct Neoplasms (Phase 2)

Cholangiocarcinoma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1